Last updated on May 2019

Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia

Brief description of study

Phase I, first-in-human, open-label, dose-finding study of UCART123 administered intravenously to patients with Acute Myeloid Leukemia (AML), followed by a dose escalation stage in relapsed or refractory AML patients and a dose-expansion stage in relapsed/refractory AML patients, and in poor-prognosis, newly diagnosed AML patients in the European LeukemiaNet (ELN) adverse genetic risk group.

Clinical Study Identifier: NCT03190278

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.